Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
On-demand video webcast now available here PRINCETON, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the ...
Claude 3.7 Sonnet debuts with “extended thinking” to tackle complex problems
On Monday, Anthropic announced Claude 3.7 Sonnet, a new AI language model with a simulated reasoning (SR) capability called " ...
CDOTrends4d
Claude 3.7 Sonnet Takes Back the AI Crown
Based on results across various benchmarks, Claude 3.7 Sonnet is back in the lead in the white-hot race for AI supremacy, ...
Weekly Tech Recap: OpenAI launches GPT 4.5, Claude gets Sonnet 3.7 update and more
Meta plans to launch a standalone app for its AI, Anthropic has launched Claude 3.7 Sonnet, a new language model. Google’s ...
Nasdaq5d
Sonnet BioTherapeutics Holdings, Inc. Announces Availability of On-Demand Video Webcast Following Virtual Investor "Top 5 for ‘25" Conference
Sonnet BioTherapeutics Holdings, Inc. recently participated in the Virtual Investor "Top 5 for ‘25” On-Demand Conference, where CEO Pankaj Mohan, Ph.D., outlined five reasons for the ...
Yahoo Finance5d
Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced it participated in the Virtual Investor "Top 5 for ...
The Truth About GPT-4.5: Strengths, Weaknesses and Costs
Explore key differences, creative applications, and whether the price increase is justified for your needs. Uncover GPT-4.5 ...